BRIEF: Kalytera Therapeutics – Four Critical Points
Kalytera Therapeutics (TSXV: KALY) investors had quite the hay day yesterday. At the close, it finished up $0.095, or 38%
Read more
KALY
the deep dive
Providing stock analysis for investors of the Canadian junior markets